Audentes Therapeutics (NASDAQ:BOLD) Upgraded by Citigroup to “Neutral”

Share on StockTwits

Audentes Therapeutics (NASDAQ:BOLD) was upgraded by research analysts at Citigroup from a “sell” rating to a “neutral” rating in a research note issued on Tuesday, The Fly reports.

A number of other research analysts also recently weighed in on BOLD. Guggenheim downgraded Audentes Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday. Zacks Investment Research downgraded Audentes Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. ValuEngine lowered Audentes Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Evercore ISI raised Audentes Therapeutics from an “in-line” rating to an “outperform” rating in a research note on Wednesday, November 27th. Finally, Robert W. Baird raised shares of Audentes Therapeutics from an “underperform” rating to a “neutral” rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $42.00.

Audentes Therapeutics stock opened at $28.61 on Tuesday. The company has a market cap of $1.33 billion, a P/E ratio of -8.41 and a beta of 1.77. Audentes Therapeutics has a fifty-two week low of $17.95 and a fifty-two week high of $41.65. The firm’s 50 day simple moving average is $27.71 and its 200-day simple moving average is $33.11.

Audentes Therapeutics (NASDAQ:BOLD) last released its earnings results on Thursday, November 7th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.07) by $0.07. During the same period in the previous year, the business posted ($0.97) earnings per share. As a group, research analysts predict that Audentes Therapeutics will post -4.13 earnings per share for the current fiscal year.

In other news, Director Louis G. Lange sold 10,000 shares of the stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $32.16, for a total transaction of $321,600.00. Following the transaction, the director now owns 276,044 shares of the company’s stock, valued at approximately $8,877,575.04. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Matthew R. Patterson sold 14,426 shares of the stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $30.00, for a total value of $432,780.00. Following the transaction, the chief executive officer now directly owns 127,820 shares in the company, valued at approximately $3,834,600. The disclosure for this sale can be found here. 5.30% of the stock is owned by insiders.

Institutional investors have recently made changes to their positions in the business. Meeder Asset Management Inc. grew its holdings in Audentes Therapeutics by 578.5% during the second quarter. Meeder Asset Management Inc. now owns 726 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 619 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Audentes Therapeutics by 50.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,990 shares of the biotechnology company’s stock worth $113,000 after buying an additional 1,005 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of Audentes Therapeutics by 1.8% during the 3rd quarter. Rhumbline Advisers now owns 61,051 shares of the biotechnology company’s stock worth $1,715,000 after buying an additional 1,070 shares during the period. Aperio Group LLC bought a new stake in shares of Audentes Therapeutics during the 2nd quarter worth $46,000. Finally, Swiss National Bank boosted its holdings in shares of Audentes Therapeutics by 2.1% during the 2nd quarter. Swiss National Bank now owns 67,500 shares of the biotechnology company’s stock worth $2,556,000 after buying an additional 1,400 shares during the period. 98.08% of the stock is owned by hedge funds and other institutional investors.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

See Also: Calculating net profit and net profit margin ratio

The Fly

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.